Skip to content
Live funding
Ki 13 €4.3M Seed round led by HICO Investment Group Conveo €43.2M Series A round led by DST Global Partners iPronics €108M Series B round led by Maverick Silicon iPremom €15M Seed round led by Amadeus Capital Partners Pharosyn €2.6M Seed round led by Moonfire Ventures HyImpulse €50M Series A round led by JOIN Capital Instarc €1.3M Seed round led by HFO Investments Holifya €1.6M Seed round led by Next Age (CDP Venture Capital) Full Health Medical €3M Seed round led by Elkstone Captive Devices €870K funding round led by Oxford Metrics (Vicon) PLD Space €108M Series C round led by Mitsubishi Electric Corporation Orchestra €2.9M Seed round led by Differential Ventures INLEAP Photonics €20M Seed round led by UVC Partners xorlab €5M Series A round led by Spicehaus Partners Scan.com €77.5M Series C round led by Noteus Partners Nexeon €116.7M Growth round led by National Wealth Fund S-Transistors €2.6M Pre-seed round led by Lifeline Ventures Motion €1.7M Pre-seed round led by Extantia Capital Breedr €23.2M Series B round led by Partech Embedd €2.3M Pre-seed round led by Seedcamp
Sesame Summit 2027
Sesamers

Agoranov

Incubator · Paris, France · Up to 23 months
Rolling applications Apply
No direct cheque; access to a non-dilutive grant pipeline Cheque
None Equity
Up to 23 months Length
Paris, France Where

Twenty-three months is the outside limit of a residency at Agoranov, which is longer than most accelerator places and reflects what it is built for: research spin-offs and science-led companies in biotech and deep tech, where the road to a product is measured in years rather than quarters.

The incubator is publicly backed and based in Paris. It writes no cheque of its own. What it provides is the residency, coaching, and access to a pipeline of non-dilutive grants, and it takes no equity for any of it.

Entry is rolling rather than by cohort.

What it actually costs you

ChequeNo direct cheque; access to a non-dilutive grant pipeline
Equity takenNone

Agoranov is a publicly backed Paris incubator built around research spin-offs and science-led companies in biotech and deep tech. Residency runs up to 23 months and comes with coaching and access to a non-dilutive grant pipeline; there is no direct cheque and no equity is taken, so founders keep their cap table intact. Intake is rolling rather than cohort-based.

Get the weekly briefing Europe's rounds, founders & events - every Monday, in five minutes.